

# Redefining the Lines of TNBC

**Real-world management: Improving survival for patients with metastatic TNBC**

Sunday, 11 September 2022 | 13:00–14:30 CEST  
7.3.T – Toulouse Auditorium, Hall 7, Level 7.3,  
Paris Expo Porte de Versailles, Paris, France

# Dear Colleague,

We are pleased to invite you to the Gilead symposium, Redefining the Lines of TNBC, where our expert-led panel will explore how we can improve outcomes for our patients with metastatic TNBC.

There is still a high unmet need for metastatic TNBC patients, and it is paramount to work together to increase survival for these patients.

In this symposium, we will examine the current TNBC treatment landscape and the remaining challenges facing patients and physicians.

Using interactive patient case studies, we would like to engage the audience in relevant discussions on optimal real-world management and provide guidance on how to incorporate innovative therapies into clinical practice.

We look forward to welcoming you on Sunday, 11 September at 13:00. Let's come together to improve outcomes for our patients with metastatic TNBC.

## Agenda

**TNBC today: How can we increase survival for a very heterogeneous and aggressive disease?**



**Dr Suzette Delaloge (Chair)**

*Associate Professor of Medical Oncology,  
Department of Cancer Medicine,  
Gustave Roussy, France*

**Treatment milestones in TNBC and current treatment pathway**



**Prof. Alessandra Gennari**

*Associate Professor of Oncology at the University of Eastern Piedmont (UPO) and Head of the Division of Oncology at Maggiore University Hospital, Novara, Italy*

**Real-world management of TNBC: Incorporating new therapies into clinical practice**



**Dr Komal Jhaveri**

*Associate Attending Physician, Breast Medicine Service and Early Drug Development Service, Section Head of the Endocrine Therapy Research Program, and Clinical Director of the Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Assistant Professor of Medicine, Weill Cornell Medical College, New York, USA*



**Prof. Dr Sherko Kümmel**

*Clinical Director of Interdisciplinary Breast Unit, Lead of Breast Cancer Research Programme, Kliniken Essen-Mitte, Germany*

**Key considerations when managing patients with mTNBC: Faculty insights and audience Q&A**

**All faculty; facilitated by Dr Suzette Delaloge**